מדינה: ניו זילנד
שפה: אנגלית
מקור: Medsafe (Medicines Safety Authority)
Leuprorelin acetate 5 mg/mL
AbbVie Limited
Leuprorelin acetate 5 mg/mL
5 mg/mL
Solution for injection
Active: Leuprorelin acetate 5 mg/mL Excipient: Benzyl alcohol Glacial acetic acid Sodium chloride Sodium hydroxide Water for injection
Vial, glass, 2.8 mL
Prescription
Prescription
Takeda Pharmaceutical Company Limited
Lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
Package - Contents - Shelf Life: Vial, glass, - 2.8 mL - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light
1985-12-05
Lucrin 5 mg/mL DS Version 5 08 February 2018 Page 1 of 12 NEW ZEALAND DATA SHEET 1. LUCRIN ® 5 MG/ML SOLUTION FOR INJECTION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL contains 5 mg of leuprorelin acetate. EXCIPIENTS WITH KNOWN EFFECT Benzyl alcohol For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for Injection. Lucrin is a sterile, clear aqueous solution intended for subcutaneous injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS PROSTATE CANCER Lucrin (leuprorelin acetate) is indicated • in metastatic prostate cancer, • in locally advanced prostate cancer, as an alternative to surgical castration, • as an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer, • as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression. ASSISTED REPRODUCTIVE TECHNIQUES Lucrin is also indicated for controlled ovarian hyperstimulation for _in-vitro_ fertilisation or other assisted reproductive technique options. 4.2 DOSE AND METHOD OF ADMINISTRATION Leuprorelin acetate must be administered under the supervision of a physician. Parenteral products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. Lucrin 5 mg/mL DS Version 5 08 February 2018 Page 2 of 12 PROSTATE CANCER The recommended dose is 1 mg (0.2 mL) administered as a single daily subcutaneous injection. As with other medicines administered chronically by subcutaneous injection, the injection site should be varied periodically. In patients treated with GnRH analogues for prostate cancer, treatment is usually continued upon development of castration-resistant prostate cancer. Reference should be made to relevant guidelines. ASSISTED REPRODUCTIVE TECHNIQUES _Long protocol: _ The maximum recommended daily dose of leuprorelin acetate is 1 mg (0.2 mL) administered by subcutaneous injection. The treatment m קרא את המסמך השלם